Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates, Poolbeg Pharma holds licensed access to advanced micro- and nanoencapsulation technology. This technology is being leveraged to develop an oral vaccine delivery platform capable of transporting immune-stimulating antigens to specific areas of the gut. The company also utilizes an artificial intelligence-powered program to aid in drug discovery. Furthermore, Poolbeg Pharma is developing a biomarker platform with the goal of identifying individuals at risk of progressing to severe disease. It also operates a sophisticated, model-derived vaccine discovery platform dedicated to uncovering novel vaccine candidates. The company was incorporated in 2021.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.